Peringkat dalam Saham
#17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Kapitalisasi Pasar
$12.78M
Perubahan (1 tahun)
-22.01%
Perdagangan Noxopharm Limited (NOX)
Margin Operasi untuk Noxopharm Limited (NOX)
Margin Operasi per March 2026 TTM: -532.32%
Menurut laporan keuangan dan harga saham terbaru dari Noxopharm Limited, margin operasi saat ini (TTM) adalah -532.32%. Pada akhir 2024, margin operasi perusahaan adalah -313.92%.
Riwayat margin operasi untuk Noxopharm Limited dari 2016 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun |
Margin Operasi |
Mengubah |
|
2026 (TTM) |
-532.32%
|
55.59%
|
|
2025 |
-342.14%
|
8.99%
|
|
2024 |
-313.92%
|
13.69%
|
|
2023 |
-276.12%
|
-1.43%
|
|
2022 |
-280.14%
|
7.54%
|
|
2021 |
-260.50%
|
31.83%
|
|
2020 |
-197.61%
|
-52.69%
|
|
2019 |
-417.69%
|
-63.54%
|
|
2018 |
-1,145.69%
|
-55.34%
|
|
2017 |
-2,565.11%
|
0.00%
|
|
2016 |
0.00%
|
0.00%
|
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan |
Margin Operasi |
Perbedaan Margin Operasi |
Negara |
|
|
41.30% |
-100.08%
|
DK
|
|
|
35.45% |
-100.07%
|
US
|
|
|
24.95% |
-100.05%
|
US
|
|
|
25.32% |
-100.05%
|
BE
|
|
|
25.72% |
-100.05%
|
AU
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.
